Psychiatric adverse events during levetiracetam therapy.
about
Monotherapy for partial epilepsy: focus on levetiracetamReview of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizuresLevetiracetam in the treatment of epilepsyEpilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based ReviewPerampanel for focal epilepsy: insights from early clinical experienceThe treatment of depressive disorders in epilepsy: what all neurologists should knowDepression and anxiety in people with epilepsyBrivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence baseSelf-reported feelings of anger and aggression towards others in patients on levetiracetam: data from the UK antiepileptic drug register.Suicide-related behaviors in older patients with new anti-epileptic drug use: data from the VA hospital systemLevetiracetam-induced acute psychosis in a childZonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control studyBeneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy: a summary of prevalence, underlying mechanisms and data limitations.An update on antiepileptic drugs and suicide: are there definitive answers yet?Negative effects of antiepileptic drugs on mood in patients with epilepsy.Psychosis of epilepsy: a multifaceted neuropsychiatric disorder.Homicide during postictal psychosis.Lennox-lombroso lecture, 2013: psychiatric comorbidities through the life of the seizure disorder: a complex relation with a not so complex solution.Clear indications of emotion depend on vivid stimuli.New drugs for the treatment of epilepsy: a practical approachMechanisms of action for the commonly used antiepileptic drugs: relevance to antiepileptic drug-associated neurobehavioral adverse effects.Behavioral and psychiatric adverse events associated with antiepileptic drugs commonly used in pediatric patients.Diagnosis and management of depression and psychosis in children and adolescents with epilepsy.Use of psychotropic drugs in patients with epilepsy: interactions and seizure risk.Antiepileptic drugs and the regulation of mood and quality of life (QOL): the evidence from epilepsy.Effects of antiepileptic drugs on mood and behavior.Potential of levetiracetam in mood disorders: a preliminary review.Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain.Suicidality and antiepileptic drugs: is there a link?Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug.The safety of levetiracetam.Levetiracetam Extended Release as Adjuvant Therapy for the Control of Partial-onset Seizures.Psychiatric manifestations of neurologic disease: where are we headed?Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2)CNS adverse events associated with antiepileptic drugs.Epilepsy pharmacogenetics.Suicidality and epilepsy: a complex relationship that remains misunderstood and underestimated.The FDA alert on suicidality and antiepileptic drugs: Fire or false alarm?Psychopharmacological issues in the treatment of TBI and PTSD.Depression in epilepsy: a critical review from a clinical perspective.
P2860
Q24644605-CD56D458-4344-480A-A20E-535A2C5A1433Q24650880-F0595EC5-75F5-418C-9406-3B2F0EF65F47Q24656333-BF609023-DBF6-478B-95B0-CE43302E565DQ26743786-6E1C902B-2D08-40A0-84C2-D3AC8C5A4980Q26778392-E98B12EC-7B3E-4BB8-BCFA-734B179BD88DQ26851858-F624BCB4-6C7E-4E24-8C94-48F7AC096120Q27008273-F9B8A298-E676-48C7-B181-7251D933B9A0Q28076065-A82FFC98-E329-419E-9FBF-65600681CF3EQ30604685-45D02876-F48A-4022-9571-712903C09B0DQ33523160-C002EAD7-BA43-4441-ABDA-74629C129706Q33809434-7FAA75BF-589B-44A9-8899-66DA7D1B3A2BQ34053280-86C785FD-95CF-4905-9301-093EB9511A27Q34186198-1CA97806-E060-429B-B570-7132B9E92C9FQ34401213-E0C34AE3-3366-4F69-A56B-AFE3C9546F90Q34580773-EFE38F25-2B2E-440B-B9D6-A4CC1023F8B9Q34677575-39A93251-7876-4927-BE7E-7941913FEC94Q35018842-29C9A3D2-BC71-4487-A743-C41A2CE6CDF2Q35076352-6FD6FF70-5DD9-4C96-A63D-FF015FE2B258Q35478174-755CF4B4-4301-4F28-B085-446466E21B46Q35520425-97757C4A-78AB-403E-A862-AEC378410B0EQ35939580-B4B2CCEE-8AD7-4AF0-9793-29648CC84979Q35939591-54B8A592-8BE5-4630-B09A-F4B408F281D8Q35941091-6C3179AE-DB8E-45CA-AAB1-3846CF6CA366Q36106896-91DAA906-1E3A-448B-9904-65DBD787AD1CQ36169546-014FEFA0-68AB-452F-BF31-73AC6C803FEDQ36653769-1595E648-5B41-45CA-B6B4-0B8FD357B265Q36670842-E5BABB40-8F7B-4DC9-ACDF-30A145049B2DQ36697477-31C189EA-13D4-4791-9A34-8FB6771517DBQ36718436-3503147E-9C86-4E3F-9B9C-42002BD83A39Q36802676-F96551AF-42F6-485D-86B7-878CF7D75703Q36811528-AB21B8FF-958D-4DC0-BD87-41DF6F4DA7FEQ36873888-4422620B-FC2C-4EFA-B220-C68A5B1DC86EQ36922117-5DA8C110-BEC8-436D-8179-9A699A2D7F77Q37242260-1668107C-1A26-4828-9246-0A703653DEBAQ37242600-96E7D19F-5473-4E56-822B-5E2BC3AABCB9Q37486720-22D850D4-F045-43F5-8427-3B59E7B2CDDAQ37496670-D9371410-6341-44F7-AB05-334D686D6BB3Q37508121-B637DAE7-025F-4149-A71A-EF322B5A596DQ37625940-4373B6A2-7B97-425A-9260-94F20E3F95CBQ37900481-A09AC413-A2E2-4993-8C74-FB915E7551C9
P2860
Psychiatric adverse events during levetiracetam therapy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Psychiatric adverse events during levetiracetam therapy.
@en
Psychiatric adverse events during levetiracetam therapy.
@nl
type
label
Psychiatric adverse events during levetiracetam therapy.
@en
Psychiatric adverse events during levetiracetam therapy.
@nl
prefLabel
Psychiatric adverse events during levetiracetam therapy.
@en
Psychiatric adverse events during levetiracetam therapy.
@nl
P2093
P1433
P1476
Psychiatric adverse events during levetiracetam therapy.
@en
P2093
P304
P356
10.1212/01.WNL.0000078031.32904.0D
P407
P577
2003-09-01T00:00:00Z